Melanoma is a highly aggressive form of skin cancer that originates from melanocytes, the specialized cells responsible for producing melanin, the pigment that gives skin its color. Unlike many other skin cancers, melanoma can develop on any area of the skin, including parts that are not typically exposed to the sun, as well as in the eyes (ocular melanoma) or mucous membranes. The cancer is particularly dangerous because it has a high potential to invade deeper layers of the skin, enter the lymphatic system, and metastasize to distant organs such as the lungs, liver, brain, and bones. Early detection significantly improves prognosis, which is why awareness of changing moles or new skin lesions is critical. Melanoma is classified into five stages, primarily based on tumor thickness (measured in millimeters), the presence or absence of ulceration, involvement of regional lymph nodes, and distant metastasis. Stage 0 (Melanoma in situ) is the earliest form, confined to the epidermis, with cancer cells present only in the top skin layer; it is highly treatable with almost complete cure rates if excised. Stage I involves a tumor up to 2 mm thick, which may or may not have ulceration, but has not yet spread to lymph nodes or distant organs. Stage II is characterized by thicker tumors (14 mm with ulceration, or more than 4 mm without ulceration) that are still localized, without lymph node involvement or metastasis. Stage III indicates regional spread to nearby lymph nodes or small areas of skin near the primary tumor (satellite or in-transit metastases), with tumor thickness and ulceration varying depending on the subtype. Finally, Stage IV represents advanced melanoma with distant metastasis, often affecting organs such as the lungs, liver, brain, or bones, which significantly worsens prognosis and requires intensive systemic treatments including immunotherapy, targeted therapy, or combination approaches.

Melanoma risk is influenced by a combination of genetic, environmental, and personal factors. Ultraviolet (UV) radiation exposure is the leading environmental risk, with both natural sunlight and artificial tanning beds contributing to DNA damage in skin cells. Individuals with fair skin, light-colored hair, and light eyes have less melanin, reducing natural protection against UV-induced mutations. Family history also plays a significant role; having a first-degree relative with melanoma substantially increases ones susceptibility, reflecting inherited genetic predispositions. A personal history of skin cancer, including prior melanoma or non-melanoma skin cancers, raises the likelihood of recurrence or new tumors. The presence of numerous moles (nevi) or atypical/dysplastic moles is another critical risk factor, as these lesions can undergo malignant transformation. A weakened immune system, whether due to HIV/AIDS, immunosuppressive medications, or organ transplantation, diminishes the bodys ability to detect and destroy abnormal cells. Although melanoma can occur at any age, risk increases with age, particularly in adults over 50, due to cumulative UV exposure and declining cellular repair mechanisms.

Melanoma often develops on sun-exposed areas such as the back, legs, arms, and face, but it can occur anywhere, including under nails or on the soles of the feet. Early detection relies heavily on visual changes in moles or skin lesions, summarized by the ABCDE rule: Asymmetry, where one half of a mole does not match the other; Border irregularity, with edges that are notched, scalloped, or blurred; Color variation, showing multiple shades like black, brown, red, white, or blue within the same lesion; Diameter larger than 6 mm, roughly the size of a pencil eraser; and Evolving, meaning the mole changes over time in size, shape, or color. Additional warning signs include sores that fail to heal, itching, tenderness, or pain in a mole, and bleeding or oozing from a lesion.

Diagnosis of melanoma involves a comprehensive approach combining clinical evaluation, specialized imaging, and laboratory analysis to confirm the presence of cancer and assess its extent. Initially, a dermatologist performs a thorough skin examination, inspecting moles or suspicious lesions for changes in size, shape, color, or texture, often using the ABCDE criteria to identify high-risk features. Dermoscopy may be employed, which uses a magnifying tool with light to examine structures beneath the skin surface, enhancing the detection of atypical or malignant patterns. The definitive diagnosis is made through a skin biopsy, where a portion or the entirety of the suspicious lesion is removed via shave, punch, or excisional techniques and analyzed microscopically to determine melanoma type, depth (Breslow thickness), and ulceration status. In cases where the melanoma is of significant thickness or shows high-risk characteristics, a sentinel lymph node biopsy is performed to check for regional spread, providing critical information for accurate staging. For suspected advanced disease or metastasis, imaging studies such as CT scans, MRI, or PET scans are used to evaluate the involvement of distant organs like the lungs, liver, or brain.

Treatment of melanoma is tailored to the stage, location, and molecular characteristics of the tumor, often combining surgical, systemic, and supportive approaches to maximize outcomes. Surgery is the primary treatment for localized melanoma, involving a wide local excision to remove the tumor along with a margin of healthy tissue to reduce recurrence risk. If cancer has spread to regional lymph nodes, a lymph node dissection may be performed to remove affected nodes and assess further spread. For advanced or high-risk melanoma, immunotherapy using checkpoint inhibitors like nivolumab or pembrolizumab stimulates the immune system to recognize and attack cancer cells. Patients whose tumors harbor specific genetic mutations, such as BRAF or MEK, may receive targeted therapies that inhibit the molecular pathways driving tumor growth. While less commonly used today, chemotherapy remains an option for metastatic melanoma when immunotherapy or targeted therapies are ineffective. Additionally, radiation therapy may be employed post-surgically to destroy residual cancer cells or palliatively to relieve pain and other symptoms in advanced disease.

Risk reduction for melanoma focuses on minimizing ultraviolet (UV) exposure and practicing vigilant skin monitoring. Individuals should avoid excessive sun exposure, especially during peak hours, and consistently use broad-spectrum sunscreen with SPF 30 or higher on all exposed skin. Wearing protective clothing, wide-brimmed hats, and UV-blocking sunglasses further reduces risk, while tanning beds should be avoided entirely due to their high UV output. Regular skin self-examinations help detect new or changing moles early, and annual dermatology check-ups provide professional monitoring for suspicious lesions.

Current melanoma research is focused on improving treatment outcomes and early detection. Scientists are developing new immunotherapies to enhance the immune systems ability to fight melanoma and improve survival rates, while personalized medicine approaches use genetic testing to tailor treatments to each patients tumor profile. Artificial intelligence (AI) and advanced imaging technologies are being explored to detect melanoma earlier and more accurately, potentially identifying high-risk lesions before they progress. Additionally, researchers are investigating novel vaccine strategies aimed at preventing melanoma recurrence, offering hope for long-term disease control.

1. Can melanoma be cured? Yes, early-stage melanoma is highly curable, often with simple surgical removal. The prognosis is excellent when caught before it spreads. However, advanced melanoma may require ongoing treatment with immunotherapy or targeted therapy. While it may not always be curable at that stage, it can often be effectively managed for extended periods. 2. What happens if melanoma is left untreated? If left untreated, melanoma can spread to other organs, including the lymph nodes, lungs, liver, brain, or bones. This progression makes the disease much harder to treat and potentially life-threatening, underscoring the importance of early detection and prompt treatment. 3. Can melanoma come back after treatment? Yes, melanoma can recur, even after successful treatment, especially in patients with deeper or more advanced tumors. Thats why regular follow-up visits and skin checks are essential to monitor for recurrence or new melanomas. 4. How often should I check my skin for melanoma? Its recommended to perform a monthly self-examination at home to check for new or changing moles or spots. In addition, you should have a professional skin check with a dermatologist at least once a year, or more often if youre at higher risk. 5.What is the survival rate for melanoma? Survival rates depend on the stage at diagnosis. For Stage I melanoma, the 5-year survival rate is around 99%. In Stage III, it drops to about 68%, and for Stage IV (metastatic melanoma), the rate is approximately 30%. However, outcomes for advanced melanoma are improving with the development of new treatments like immunotherapy.